- amgen inc AMGN announced detailed results from the global Phase 3 CodeBreaK 200 study. These data will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress
- The data showed that oral Lumakras/Lumykras (sotorasib) resulted in significantly better progression-free survival (PFS) and a higher objective response rate (ORR). KRAS G12C mutated non-small cell lung cancer (NSCLC) compared with intravenous chemotherapy, docetaxel.
- Lumakras reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy.
- There was no significant difference in overall survival between Lumakras and intravenous chemotherapy, docetaxel.
- After one year, 24.8% of Lumakras users were alive and showing no worsening of the disease, compared to 10.1% for docetaxel.
- Related: Amgen Promotes Early Lumakras Combo Dates In KRAS Cancer Settings
- Lumakras demonstrated double response rates of 28% compared to docetaxel (13%) and demonstrated consistent benefits in other secondary efficacy endpoints, including an improved disease control rate (83% versus 60%).
- Overall survival was not significantly different between the treatment arms. The study was not designed to detect a statistical difference in OS.
- Amgen said 33% of Lumakras study patients experienced serious side effects like diarrhea and elevated liver enzymes, compared to 40% of chemotherapy patients.
- Price promotion: AMGN shares are down 3.54% to $238.92 during the premarket session last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
